Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 18, 2025
Transactions
17
Purchases
0
Sales
17
Purchase value
$0.00
Sale value
$327.56M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Baker Bros. Advisors (GP) LLCFormer 10% owner
Baker Bros. Advisors LPFormer 10% owner
Baker FelixFormer 10% owner
Baker JulianFormer 10% owner
4
Filed Jul 16, 2026Period of report Jul 14, 20260001193125-26-306299
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 14, 2026
Common StockF1F2F3
261,368
$102.50
$26.79M
442,940
IndirectSee Footnotes
SaleJul 14, 2026
Common StockF2F3F4
2,838,632
$102.50
$290.96M
4,372,852
IndirectSee Footnotes
Filing footnotes · 4
F1After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Celcuity Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F2Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
F3Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Filed May 6, 2026Period of report May 4, 20260001688319-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 4, 2026
Common StockF1F2
1,289
$137.00
$176.59K
14,471
IndirectBy Trust
SaleMay 4, 2026
Common StockF1F3F2
550
$138.9955
$76.45K
13,921
IndirectBy Trust
SaleMay 4, 2026
Common StockF1F4F2
1,670
$139.5832
$233.10K
12,251
IndirectBy Trust
SaleMay 4, 2026
Common StockF1F5F2
2,301
$141.0271
$324.50K
9,950
IndirectBy Trust
SaleMay 4, 2026
Common StockF1F6F2
2,825
$142.0358
$401.25K
7,125
IndirectBy Trust
SaleMay 4, 2026
Common StockF1F7F2
365
$143.2378
$52.28K
6,760
IndirectBy Trust
Filing footnotes · 8
F1The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2025.
F2The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
F3The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $138.255 to $139.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F4The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $139.40 to $140.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F5The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $140.50 to $141.33, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $141.59 to $142.50, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F7The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $143.20 to $143.46, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Filed Apr 2, 2026Period of report Mar 31, 20260001688319-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 31, 2026
Common StockF1F3F2
2,325
$110.1057
$256.00K
7,435
IndirectBy Trust
SaleMar 31, 2026
Common StockF1F4F2
675
$110.8268
$74.81K
6,760
IndirectBy Trust
Filing footnotes · 5
F1The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2025.
F2The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
F3The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $109.505 to $110.48, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F4The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $110.50 to $111.36, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Filed Jan 29, 2026Period of report Jan 27, 20260001296457-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJan 27, 2026
Common StockF1F2F3
20,000
$120.0269
$2.40M
90,000
IndirectBy Brightstone Venture Capital Fund, LP
Filing footnotes · 3
F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brightstone Venture Capital Fund, LP ("Brightstone") on August 19, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.315, inclusive. The reporting person undertakes to provide Celcuity Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The reporting person is the General Partner of Brightstone.
Filed Dec 9, 2025Period of report Dec 5, 20250001688319-25-000013
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 5, 2025
Common StockF2F1
1,490
$105.3398
$156.96K
8,270
IndirectBy Trust
SaleDec 5, 2025
Common StockF3F1
1,510
$106.0353
$160.11K
6,760
IndirectBy Trust
Filing footnotes · 4
F1The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
F2The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $105.00 to $105.70, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F3The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $106.00 to $106.45, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Filed Dec 3, 2025Period of report Dec 1, 20250001688319-25-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 1, 2025
Common StockF2F1
1,100
$98.1349
$107.95K
7,260
IndirectBy Trust
Filing footnotes · 3
F1The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
F2The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $98.010 to $98.505, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Filed Nov 24, 2025Period of report Nov 21, 20250001296457-25-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 21, 2025
Common StockF1F2F3
15,000
$100.0011
$1.50M
110,000
IndirectBy Brightstone Venture Capital Fund, LP
Filing footnotes · 3
F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brightstone Venture Capital Fund, LP ("Brightstone") on August 19, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.03, inclusive. The reporting person undertakes to provide Celcuity Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The reporting person is the General Partner of Brightstone.
Filed Nov 21, 2025Period of report Nov 19, 20250001688319-25-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 20, 2025
Common StockF2F1
3,900
$96.732
$377.25K
7,260
IndirectBy Trust
Filing footnotes · 3
F1The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
F2The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $96.465 to $96.920, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.